Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP+)

Neurotoxicity Research

Volumn 28, Issue 3, 2015, Pages 222-231

  Moretti, Morgana ^a   Neis, Vivian Binder ^a   Matheus, Filipe Carvalho ^a   Cunha, Mauricio Peña ^a   Rosa, Priscila Batista ^a   Ribeiro, Camille Mertins ^a   Rodrigues, Ana Lúcia S ^a   Prediger, Rui Daniel ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Agmatine; Antidepressant; Depression; MPP+; Parkinson s disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AGMATINE; BRAIN DERIVED NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE; ANTIDEPRESSANT AGENT;

ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; EXPERIMENTAL DEPRESSION TEST; FRONTAL CORTEX; LOCOMOTION; MALE; MOUSE; NEUROMODULATION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SPLASH TEST; STRIATE CORTEX; TAIL SUSPENSION TEST; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPLICATION; CORPUS STRIATUM; DEPRESSIVE DISORDER; DOSE RESPONSE; DRUG EFFECTS; FRONTAL LOBE; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

AGMATINE; ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FRONTAL LOBE; MALE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; TYROSINE 3-MONOOXYGENASE;

EID: 84940898213     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-015-9540-1     Document Type: Article

References (74)

1. Adler CH (2005) Nonmotor complications in Parkinson’s disease. Mov Disord 20(Suppl 11):S23–S29
2. Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, Tremblay L, Sgambato-Faure V, Broussolle E, Thobois S (2012) Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Mov Disord 27:84–89
3. Bassani TB, Gradowski RW, Zaminelli T, Barbiero JK, Santiago RM, Boschen SL, da Cunha C, Lima MM, Andreatini R, Vital MA (2014) Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson’s disease model in rats. Brain Res 1593:95–105
4. Berghauzen-Maciejewska K, Kuter K, Kolasiewicz W, Glowacka U, Dziubina A, Ossowska K, Wardas J (2014) Pramipexole but not imipramine or fluoxetine reverses the “depressive-like” behaviour in a rat model of preclinical stages of Parkinson’s disease. Behav Brain Res 271:343–353
5. Berghauzen-Maciejewska K, Wardas J, Kosmowska B, Glowacka U, Kuter K, Ossowska K (2015) Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson’s disease: an influence of chronic pramipexole in rats. PLoS One 10:e0117698
6. Bodis-Wollner I (2003) Neuropsychological and perceptual defects in Parkinson’s disease. Parkinsonism Relat Disord 9(Suppl 2):S83–S89
7. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134
8. Brown AS, Gershon S (1993) Dopamine and depression. J Neural Transm 91:75–109
9. Budni J, Gadotti VM, Kaster MP, Santos AR, Rodrigues AL (2007) Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test. Eur J Pharmacol 575:87–93
10. Castro AA, Wiemes BP, Matheus FC, Lapa FR, Viola GG, Santos AR, Tasca CI, Prediger RD (2013) Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson’s disease. Brain Res 1513:103–116
11. Chiu CC, Yeh TH, Lai SC, Wu-Chou YH, Chen CH, Mochly-Rosen D, Huang YC, Chen YJ, Chen CL, Chang YM, Wang HL, Lu CS (2015) Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism. Exp Neurol 263:244–253
12. Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann NY Acad Sci 991:1–14
13. Freitas AE, Bettio LE, Neis VB, Moretti M, Ribeiro CM, Lopes MW, Leal RB, Rodrigues AL (2014a) Sub-chronic agmatine treatment modulates hippocampal neuroplasticity and cell survival signaling pathways in mice. J Psychiatr Res 58:137–146
14. Freitas AE, Bettio LE, Neis VB, Santos DB, Ribeiro CM, Rosa PB, Farina M, Rodrigues AL (2014b) Agmatine abolishes restraint stress-induced depressive-like behavior and hippocampal antioxidant imbalance in mice. Prog Neuropsychopharmacol Biol Psychiatry 50:143–150
15. Freitas AE, Egea J, Buendia I, Navarro E, Rada P, Cuadrado A, Rodrigues AL, Lopez MG (2014c) Agmatine induces Nrf2 and protects against corticosterone effects in hippocampal neuronal cell line. Mol Neurobiol 51(3):1504–1519
16. Freitas AE, Egea J, Buendia I, Gomez-Rangel V, Parada E, Navarro E, Casas AI, Wojnicz A, Ortiz JA, Cuadrado A, Ruiz-Nuno A, Rodrigues AL, Lopez MG (2015) Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice. Mol Neurobiol. doi:10.1007/s12035-015-9182-6
17. Gilad GM, Gilad VH (2000) Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats. Neurosci Lett 296:97–100
18. Gilad GM, Gilad VH, Finberg JP, Rabey JM (2005) Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. Neurochem Res 30:713–719
19. Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, Iqbal S, Mahoney JJ 3rd, De La Garza R 2nd, Charney DS, Newton TF, Mathew SJ (2014) Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17:331–336
20. Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12:12–15
21. Hantz P, Caradoc-Davies G, Caradoc-Davies T, Weatherall M, Dixon G (1994) Depression in Parkinson’s disease. Am J Psychiatry 151:1010–1014
22. He YY, Zhang XY, Yung WH, Zhu JN, Wang JJ (2013) Role of BDNF in central motor structures and motor diseases. Mol Neurobiol 48:783–793
23. Heinz A, Schmidt LG, Reischies FM (1994) Anhedonia in schizophrenic, depressed, or alcohol-dependent patients–neurobiological correlates. Pharmacopsychiatry 27(Suppl 1):7–10
24. Hui J, Zhang J, Kim H, Tong C, Ying Q, Li Z, Mao X, Shi G, Yan J, Zhang Z, Xi G (2014) Fluoxetine regulates neurogenesis in vitro through modulation of GSK-3beta/beta-catenin signaling. Int J Neuropsychopharmacol. doi:10.1093/ijnp/pyu099
25. Itano Y, Kitamura Y, Nomura Y (1995) Biphasic effects of MPP+, a possible parkinsonism inducer, on dopamine content and tyrosine hydroxylase mRNA expression in PC12 cells. Neurochem Int 26:165–171
26. Javitch JA, D’Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173–2177
27. +-induced toxicity in cultured hippocampal and mesencephalic slices. Neuropharmacology 56:876–885
28. Kaku K, Shikimi T, Kamisaki Y, Shinozuka K, Ishino H, Okunishi H, Takaori S (1999) Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice. Clin Exp Pharmacol Physiol 26:680–683
29. Kim DJ, Kim DI, Lee SK, Suh SH, Lee YJ, Kim J, Chung TS, Lee JE (2006) Protective effect of agmatine on a reperfusion model after transient cerebral ischemia: temporal evolution on perfusion MR imaging and histopathologic findings. AJNR Am J Neuroradiol 27:780–785
30. Kozina EA, Khakimova GR, Khaindrava VG, Kucheryanu VG, Vorobyeva NE, Krasnov AN, Georgieva SG, Kerkerian-Le Goff L, Ugrumov MV (2014) Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism. J Neurol Sci 340:198–207
31. Kryzhanovskii GN, Krupina NA, Kucherianu VG (1995) A new model of an experimental depressive syndrome in rats induced by the systemic administration to the animals of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Zh Vyssh Nerv Deiat Imeni I P Pavlova 45:377–387
32. Kumari R, Kumar JB, Luthra PM (2015) Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson’s disease. Neurosci Lett 589:191–195
33. Lee WT, Hong S, Yoon SH, Kim JH, Park KA, Seong GJ, Lee JE (2009) Neuroprotective effects of agmatine on oxygen-glucose deprived primary-cultured astrocytes and nuclear translocation of nuclear factor-kappa B. Brain Res 1281:64–70
34. Lee KW, Im JY, Woo JM, Grosso H, Kim YS, Cristovao AC, Sonsalla PK, Schuster DS, Jalbut MM, Fernandez JR, Voronkov M, Junn E, Braithwaite SP, Stock JB, Mouradian MM (2013) Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson’s disease. Neurotherapeutics 10:143–153
35. Lotrich FE, Albusaysi S, Ferrell RE (2013) Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment. Neuropsychopharmacology 38:985–995
36. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Aguera-Ortiz L, Weintraub D, Riesco A, Kurtis MM, Chaudhuri KR (2015) Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord 21(6):629–634
37. Matheus FC, Aguiar AS Jr, Castro AA, Villarinho JG, Ferreira J, Figueiredo CP, Walz R, Santos AR, Tasca CI, Prediger RD (2012) Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behav Brain Res 235:263–272
38. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26:81–104
39. Moreira EL, Rial D, Aguiar AS Jr, Figueiredo CP, Siqueira JM, DalBo S, Horst H, de Oliveira J, Mancini G, dos Santos TS, Villarinho JG, Pinheiro FV, Marino-Neto J, Ferreira J, De Bem AF, Latini A, Pizzolatti MG, Ribeiro-do-Valle RM, Prediger RD (2010) Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson’s disease. J Neural Transm 117:1337–1351
40. Moretti M, Colla A, de Oliveira BG, dos Santos DB, Budni J, de Freitas AE, Farina M, Severo Rodrigues AL (2012) Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J Psychiatr Res 46:331–340
41. Moretti M, Matheus FC, de Oliveira PA, Neis VB, Ben J, Walz R, Rodrigues AL, Prediger RD (2014) Role of agmatine in neurodegenerative diseases and epilepsy. Front Biosci 6:341–359
42. Naskar A, Prabhakar V, Singh R, Dutta D, Mohanakumar KP (2015) Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. J Pineal Res 58(3):262–274
43. Neis VB, Manosso LM, Moretti M, Freitas AE, Daufenbach J, Rodrigues AL (2014) Depressive-like behavior induced by tumor necrosis factor-alpha is abolished by agmatine administration. Behav Brain Res 261:336–344
44. Neis VB, Moretti M, Manosso LM, Lopes MW, Leal RB, Rodrigues AL (2015) Agmatine enhances antidepressant potency of MK-801 and conventional antidepressants in mice. Pharmacol Biochem Behav 130:9–14
45. Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG (2002) Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 106:202–211
46. Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S (2014) Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice. Neuroscience 277:747–754
47. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50:743–755
48. Paxinos G, Franklin KBJ (2004) The mouse brain in stereotaxic coordinates. Elsevier Academic Press, Amsterdam, Boston
49. Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83:346–356
50. Raasch W, Schafer U, Chun J, Dominiak P (2001) Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br J Pharmacol 133:755–780
51. Reis DJ, Regunathan S (2000) Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 21:187–193
52. Rekha KR, Selvakumar GP, Sethupathy S, Santha K, Sivakamasundari RI (2013) Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson’s disease. J Mol Neurosci 51:851–862
53. Ren Z, Yang N, Ji C, Zheng J, Wang T, Liu Y, Zuo P (2015) Neuroprotective effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone in MPTP induced Parkinsonism model in mice. Neuropharmacology 93C:209–218
54. Ricci V, Pomponi M, Martinotti G, Bentivoglio A, Loria G, Bernardini S, Caltagirone C, Bria P, Angelucci F (2010) Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in Parkinson disease patients. J Clin Psychopharmacol 30:751–753
55. Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, Vital MA (2010) Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson’s disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 34:1104–1114
56. Sathiya S, Ranju V, Kalaivani P, Priya RJ, Sumathy H, Sunil AG, Babu CS (2013) Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of alpha-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6 J mice. Neuropharmacology 73:98–110
57. Serra PA, Sciola L, Delogu MR, Spano A, Monaco G, Miele E, Rocchitta G, Miele M, Migheli R, Desole MS (2002) The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. J Biol Chem 277:34451–34461
58. Shen YQ, Hebert G, Lin LY, Luo YL, Moze E, Li KS, Neveu PJ (2005) Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. J Neuroimmunol 158:14–25
59. Shopsin B (2013) The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsychiatr 25:113–118
60. Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 16:507–510
61. Simuni T, Sethi K (2008) Nonmotor manifestations of Parkinson’s disease. Ann Neurol 64(Suppl 2):S65–S80
62. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP (2001) Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13:187–196
63. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367–370
64. Taksande BG, Faldu DS, Dixit MP, Sakaria JN, Aglawe MM, Umekar MJ, Kotagale NR (2013) Agmatine attenuates chronic unpredictable mild stress induced behavioral alteration in mice. Eur J Pharmacol 720:115–120
65. + toxicity. Exp Neurol 263:50–62
66. Vuckovic MG, Wood RI, Holschneider DP, Abernathy A, Togasaki DM, Smith A, Petzinger GM, Jakowec MW (2008) Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 32:319–327
67. Wang W, Yang Y, Ying C, Li W, Ruan H, Zhu X, You Y, Han Y, Chen R, Wang Y, Li M (2007) Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52:1678–1684
68. Wei XL, Su RB, Wu N, Lu XQ, Zheng JQ, Li J (2007) Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats. Eur Neuropsychopharmacol 17:790–799
69. Willner P (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90–110
70. Yokoyama H, Kuroiwa H, Yano R, Araki T (2008) Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson’s disease. Neurol Sci 29:293–301
71. Zach M, Friedman A, Slawek J, Derejko M (2004) Quality of life in POLISH patients with long-lasting Parkinson’s disease. Mov Disord 19:667–672
72. Zeidan MP, Zomkowski AD, Rosa AO, Rodrigues AL, Gabilan NH (2007) Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol 565:125–131
73. Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos AR, Rodrigues AL (2002) Agmatine produces antidepressant-like effects in two models of depression in mice. NeuroReport 13:387–391
74. Zomkowski AD, Oscar Rosa A, Lin J, Santos AR, Calixto JB, Rodrigues AL (2004) Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res 1023:253–263